Princy Nirmal Kumar MD
Infectious Disease
Associate Professor of Medicine, Georgetown University
Join to View Full Profile
3800 Reservoir Rd NwWashington, DC 20007
Phone+1 202-687-0845
Fax+1 877-665-8072
Dr. Kumar is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
MedStar Health Georgetown University/Georgetown HospitalFellowship, Infectious Disease, 1988 - 1990
Hackensack Meridian Health/Englewood Hospital and Medical CenterResidency, Internal Medicine, 1985 - 1988
KASTURBA MEDICAL COLLEGEClass of 1982
Karnataka Institute of Medical ScienceClass of 1980
Kasturba Medical College ManipalClass of 1980
Certifications & Licensure
DC State Medical License 1988 - 2028
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Infectious Disease
Awards, Honors, & Recognition
- Top MD Consumers Checkbook
- CMS Meaningful Use Stage 2 Certification Centricity EMR, GE Healthcare, 2012-2013, 2015-2017
- CMS Meaningful Use Stage 2 Certification Centricity EMR, GE Healthcare, 2012-2013, 2015-2017
Clinical Trials
- Antiviral Activity and Safety of Mifepristone at 2 Doses in HIV-1 Infected Subjects Start of enrollment: 2006 Jul 01
- A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT Start of enrollment: 2008 Jul 01
- FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir Start of enrollment: 2013 Apr 25
Publications & Presentations
PubMed
- Inflammasome Activation and Oxidative Stress in SARS-CoV-2 Infection and Symptomatic Rebound.Silvia Lucena Lage, Joseph M Rocco, Cihan Oguz, Francisco Otaizo-Carrasquero, Adam Rupert
The Journal of Infectious Diseases. 2026-05-15 - Risk of obesity, diabetes, hypertension, and major adverse cardiovascular events after a switch to an integrase inhibitor: a target trial emulation in REPRIEVE.Emma M Kileel, Carlos D Malvestutto, Markella V Zanni, Emma Davies-Smith, Carl J Fichtenbaum
The Lancet. HIV. 2026-05-01 - 3 citationsSwitch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week resu...Chloe Orkin, Rosie Mngqibisa, Juan Diego Velez, Princy Kumar, Dominique L Braun
Lancet. 2026-02-07
Journal Articles
- Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1Princy Kumar, MD, The New England Journal of Medicine
Press Mentions
FDA Approves New HIV Treatment Option Studied at GeorgetownApril 21st, 2026
Medical Students Honored for Embracing Humanism in Health CareNovember 1st, 2024- Kumar Honored for Response, Mentorship During the PandemicApril 29th, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
